Access over 5,000 deals and agreements signed since 2015

DUBLIN, December 13, 2022 /PRNewswire/ — Added the Global Oncology Partnering 2017-2022: Deal trends, player and financials report ResearchAndMarkets.com Offer.

The Global Oncology Partnering 2017-2022: Deal trends, player and financials report provides insight and access to over 5,000 oncology partnerships and agreements made by the world’s leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter into partnership deals in oncology. The majority of deals are in the development phase where the licensee obtains a right or option to license the licensor’s oncology technology. These deals typically have multiple components, starting with collaborative research and development and commercializing the results.

Most of the transactions included in the report occur when a licensee acquires a right or option to license a licensor’s product or technology. Today, these deals more often have multiple components, including collaborative R&D and commercialization of the results.

The report guides readers through the broad oncology disease trends, key players and top deal values ​​to understand how, why and under what conditions companies are currently closing oncology deals.

The report presents financial deal values ​​for oncology deals, where available, listed by headline totals, upfront payments, milestones and royalties, allowing readers to analyze and compare the value of current deals.

Additionally, a comprehensive appendix will be included with each report of all oncology partner agreements signed and announced since 2017. Each deal title is linked to an online version of the deal record and, where available, the contract document via a web link, allowing for easy access to each contract document when needed.

The report also includes numerous tables and figures illustrating the trends and activity in oncology partnership and deals since 2017.

In summary, this report provides everything a potential dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.

READ :  Health Care Affordability? Graded D Or F, Say 3 In 4 Americans

report scope

  • Chapter 1 introduces the report.
  • Chapter 2 provides an overview of oncology dealmaking trends since 2017, including trends by year, deal type, development stage, technology type, and therapeutic indication.
  • Chapter 3 provides an analysis of financial transaction terms, which include total value, upfront payments, milestone payments, and royalties.
  • Chapter 4 provides an overview of the leading oncology deals since 2017. Deals are listed by headline value. The chapter features the 25 most active dealmakers in oncology along with a full list of the deals they are involved in. If the business has an SEC filed agreement, a link provides online access to the agreement.
  • Since 2017, Chapter 5 has provided full access to oncology deals whenever a deal contract is available and provides the user with direct access to contracts filed with SEC regulators. Each deal title is linked to an online version of the deal record contract document via a web link, allowing you to easily access any contract document when you need it.
  • Chapter 6 provides a comprehensive directory of all oncology partnering deals announced since 2017 by specific oncology objective. The chapter is organized by specific oncological therapeutic goals. Each deal title is linked to an online version of the deal record and, where available, the contract document via a web link, allowing for easy access to any contract document when needed.

Global Oncology Partnering 2017-2022: Deal Trends, Players and Financials Include:

  • Trends in oncology dealmaking in the biopharmaceutical industry since 2017
  • Access to headline, prepayment, milestone and royalty data
  • Access to over 5,000 oncology deal records
  • The leading oncology deals by value since 2017
READ :  The dos and don’ts of medication disposal

Global Oncology Partnering 2017-2022: Deal trends, player and financials lists the available deals by:

  • Company AZ
  • headline value
  • development status at the time of signing
  • Deal component type
  • Specific therapy goal

The analysis of actual contractual agreements enables the following points to be evaluated:

  • What are the exact granted or optional rights?
  • What is actually granted to the partner company by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the store?
  • How are sales and payments verified?
  • What is the contract period?
  • How are the main contract terms defined?
  • How are intellectual property rights managed and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, delivery and manufacture?
  • How are confidentiality and disclosure handled?
  • How to resolve disputes
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • What boilerplate clauses does the company insist on?
  • What boilerplate clauses seem to differ from partner to partner or deal type to deal type?
  • What jurisdiction does the company insist on for contract law?

Main topics covered:

summary

Chapter 1 Introduction

Chapter 2 – Trends in contract design in oncology
2.1. introduction
2.2. Oncology partnerships over the years
2.3. Oncology Partnering by Deal Type
2.4. Oncology partnerships by industry
2.5. Oncology partnerships by development stage
2.6. Oncology partnerships by technology type
2.7. Oncological partnerships according to therapeutic indication

Chapter 3 – Terms of Financial Agreements for Partnerships in Oncology
3.1. introduction
3.2. Disclosed financial terms for oncology partnerships
3.3. Oncology Partnering Headline Values
3.4. Oncology Deal Prepayments
3.5. Milestone payments for the oncology deal
3.6. Oncology royalties

READ :  Appellate court throws out J&J's controversial two-step bankruptcy case - Endpoints News

Chapter 4 – Leading Oncology Deals and Dealmakers
4.1. introduction
4.2. Most active in oncology partnering
4.3. List of the most active dealmakers in oncology
4.4. Top Oncology Deals by Value

Chapter 5 – Oncology Contractual Document Index
5.1. introduction
5.2. Oncology partnerships where contractual documentation is available

Chapter 6 – Oncology Business Deals by Therapeutic Goal
6.1. introduction
6.2. Offers based on the therapeutic goal of oncology

Attachments
Appendix 1 – Directory of Oncology Offerings by Companies AZ since 2017
Appendix 2 – Oncology deal directory by deal type since 2017
Appendix 3 – Index of Oncology Services by Development Stage since 2017
Appendix 4 – Index of oncology offerings by technology type since 2017

The report includes offers for the following indications:

  • Oral mucositis
  • cancer pain
  • Bone
  • neuropathic
  • Muscular
  • lymphedema
  • alopecia
  • cachexia
  • ulcers
  • dysphagia
  • fatigue
  • weight loss
  • nausea
  • Vomit
  • chemotherapy
  • radiotherapy
  • adenocarcinoma
  • basal cell carcinoma
  • bile duct cancer
  • bladder cancer
  • bone cancer
  • brain tumor
  • breast cancer
  • cervical cancer
  • colon cancer
  • endometrium
  • esophageal cancer
  • stomach cancer
  • head and neck cancer
  • Kaposi’s sarcoma
  • kidney cancer
  • leukemia
  • Acute Lymphocytic Leukemia
  • Acute myeloid leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic myeloid leukemia
  • liver cancer
  • lung cancer
  • Small cell lung cancer
  • Non-small cell lung cancer
  • lymphoma
  • Hodgkin lymphoma
  • Non-Hodgkin Lymphoma
  • melanoma
  • mesothelioma
  • metastases
  • bone metastases
  • multiple myeloma
  • neuroblastoma
  • Non-melanoma skin cancer
  • ovarian cancer
  • pancreatic cancer
  • prostate cancer
  • renal cell carcinoma
  • sarcoma
  • Solid tumors
  • testicular cancer
  • thyroid cancer

For more information about this report, visit https://www.researchandmarkets.com/r/myr7e

Media contact:
research and markets
Laura WoodSenior managers
[email protected]

For EST office hours, call +1-917-300-0470
For US/CAN, call toll free +1-800-526-8630
For GMT office hours, call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Leave a Reply

Your email address will not be published. Required fields are marked *